BioNTech to seek approval soon for vaccine for 5-11 year olds-Spiegel
10/09/2021 07:42
FRANKFURT, Sept 10 (Reuters) - BioNTech 22UAy.DE is set to
request approval across the globe for use of its COVID-19
vaccine in children as young as five over the next few weeks and
preparations for a launch are well on track, two of the biotech
firm's top executives told Der Spiegel.
"Already over the next few weeks we will file the results of
our trial in five to 11 year-olds with regulators across the
world and will request approval of the vaccine in this age
group, also here in Europe," Chief Medical Officer Oezlem
Tuereci told the weekly magazine.
She added final production steps were being adjusted to
bottle a lower-dose pediatric version of its established
Comirnaty vaccine, jointly developed with Pfizer PFE.N . It is
currently approved for adults and children over 12.
The raw trial data was now being prepared for a regulatory
filing and "things are looking good, everything is going
according to plan," Chief Executive Ugur Sahin told Der Spiegel.
(Reporting by Ludwig Burger, editing by Emma Thomasson)
((ludwig.burger@thomsonreuters.com; +49 30 220133634; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))